Loading...
Professional-patient discrepancies in assessing lung cancer radiotherapy symptoms: an international multicentre study
Aguado-Barrera, M. E. Lopez-Pleguezuelos, C. Gómez-Caamaño, A. Calvo-Crespo, P. Taboada-Valladares, B. Azria, D. Boisselier, P. Briers, E. Chan, C. Chang-Claude, J.
Aguado-Barrera, M. E.
Lopez-Pleguezuelos, C.
Gómez-Caamaño, A.
Calvo-Crespo, P.
Taboada-Valladares, B.
Azria, D.
Boisselier, P.
Briers, E.
Chan, C.
Chang-Claude, J.
Abstract
BACKGROUND AND PURPOSE: We investigate discrepancies in the assessment of treatment-related symptoms in lung cancer between healthcare professionals and patients, and factors contributing to these discrepancies. MATERIALS AND METHODS: Data from 515 participants in the REQUITE study were analysed. Five symptoms (cough, dyspnoea, bronchopulmonary haemorrhage, chest wall pain, dysphagia) were evaluated both before and after radiotherapy. Agreement between healthcare professionals and people with lung cancer was quantified using Gwet's-AC(2) coefficient. The influence of clinical variables, comorbidities, and quality-of-life outcomes on agreement was examined through stratified analyses. RESULTS: We found varying levels of agreement between healthcare professionals and people with lung cancer. Bronchopulmonary haemorrhage and dysphagia exhibited very good agreement (meanAC(2) > 0.81), while cough and chest wall pain showed substantial agreement (meanAC(2) = 0.64 and 0.76, respectively). Dyspnoea had the lowest agreement (meanAC(2) = 0.59), with prior chemotherapy significantly reducing agreement levels. Chronic obstructive pulmonary disease (COPD) and early cancer stages also contributed to discrepancies in dyspnoea assessments. Regarding quality-of-life, the most relevant factor was fatigue, which reduced agreement in the assessment of dyspnoea (AC(2) = 0.55 vs 0.70), dysphagia (AC(2) = 0.48 vs 0.69), cough (AC(2) = 0.58 vs 0.82), and chest wall pain (AC(2) = 0.77 vs 0.91). CONCLUSIONS: Our findings indicate strong alignment between healthcare professionals' and people with lung cancer evaluations of observable treatment-related symptoms, but less consistency for subjective symptoms such as dyspnoea. Factors such as prior chemotherapy, COPD, and cancer stage should be considered when interpreting symptom assessments. Furthermore, our study underscores the importance of integrating quality-of-life considerations, particularly fatigue, into symptom evaluations to mitigate potential biases in symptom perception.
Authors
Aguado-Barrera, M. E.
Lopez-Pleguezuelos, C.
Gómez-Caamaño, A.
Calvo-Crespo, P.
Taboada-Valladares, B.
Azria, D.
Boisselier, P.
Briers, E.
Chan, C.
Chang-Claude, J.
Coedo-Costa, C.
Crujeiras-González, A.
Cuaron, J. J.
Defraene, G.
Elliott, R. M.
Faivre-Finn, C.
Franceschini, M.
Fuentes-Rios, O.
Galego-Carro, J.
Gutiérrez-Enríquez, S.
Heumann, P.
Higginson, D. S.
Johnson, K.
Lambrecht, M.
Lang, P.
Lievens, Y.
Mollà, M.
Ramos, M.
Rancati, T.
Rattay, T.
Rimner, A.
Rosenstein, B. S.
Sangalli, C.
Seibold, P.
Sperk, E.
Stobart, H.
Symonds, P.
Talbot, C. J.
Vandecasteele, K.
Veldeman, L.
Ward, T.
Webb, A.
Woolf, D.
de Ruysscher, D.
West, C. M. L.
Vega, A.
Lopez-Pleguezuelos, C.
Gómez-Caamaño, A.
Calvo-Crespo, P.
Taboada-Valladares, B.
Azria, D.
Boisselier, P.
Briers, E.
Chan, C.
Chang-Claude, J.
Coedo-Costa, C.
Crujeiras-González, A.
Cuaron, J. J.
Defraene, G.
Elliott, R. M.
Faivre-Finn, C.
Franceschini, M.
Fuentes-Rios, O.
Galego-Carro, J.
Gutiérrez-Enríquez, S.
Heumann, P.
Higginson, D. S.
Johnson, K.
Lambrecht, M.
Lang, P.
Lievens, Y.
Mollà, M.
Ramos, M.
Rancati, T.
Rattay, T.
Rimner, A.
Rosenstein, B. S.
Sangalli, C.
Seibold, P.
Sperk, E.
Stobart, H.
Symonds, P.
Talbot, C. J.
Vandecasteele, K.
Veldeman, L.
Ward, T.
Webb, A.
Woolf, D.
de Ruysscher, D.
West, C. M. L.
Vega, A.
Description
Date
2025
Publisher
Collections
Files
Loading...
Found from Unpaywall
Adobe PDF, 1.77 MB
Keywords
Type
Article
Citation
Aguado-Barrera ME, Lopez-Pleguezuelos C, Gómez-Caamaño A, Calvo-Crespo P, Taboada-Valladares B, Azria D, et al. Professional-patient discrepancies in assessing lung cancer radiotherapy symptoms: An international multicentre study. Lung cancer (Amsterdam, Netherlands). 2025 Jan;199:108072. PubMed PMID: 39740425. Epub 2025/01/01. eng.